Last reviewed · How we verify
Twinrix for ATN 025
Twinrix, marketed by the University of North Carolina, Chapel Hill, is a combination vaccine that protects against both hepatitis A and B, positioning it uniquely in the dual-virus prevention market. Its key strength lies in its ability to stimulate the immune system to produce antibodies against both viruses simultaneously, offering a more convenient and comprehensive vaccination option compared to single-disease alternatives like Havrix and Engerix-B. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Twinrix for ATN 025 |
|---|---|
| Also known as | There are no other names. |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Vaccine |
| Target | Hepatitis A virus and Hepatitis B virus |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |